Acute Spinal Cord Injury (SCI)
2
Pipeline Programs
2
Companies
3
Clinical Trials
2 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2024
2025
2026
2027
2028
2029
TechnoPhageEletriptan HBr 40 mg
NovaGo TherapeuticsNG004
NovaGo TherapeuticsNG004
Clinical Trials (3)
Total enrollment: 168 patients across 3 trials
Phase 1b/2a Clinical Trial to Determine the Safety, Tolerability and Efficacy of TZ-161 in Spinal Cord Injury
Start: Aug 2025Est. completion: Jun 202728 patients
Phase 1/2Recruiting
NG004 in Incomplete Spinal Cord Injury Patients
Start: Aug 2026Est. completion: Jul 2029120 patients
Phase 1Recruiting
NG004 in Spinal Cord Injury Patients
Start: Dec 2024Est. completion: Mar 202720 patients
Phase 1Active Not Recruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 actively recruiting trials targeting 168 patients
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.